Home › Compare › GRCL vs DIVO

GRCL vs DIVO: Dividend Comparison 2026

GRCL yields 19.51% · DIVO yields 6.62%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRCL wins by $39.9K in total portfolio value
10 years
GRCL
GRCL
● Live price
19.51%
Share price
$10.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$70.9K
Annual income
$6,394.90
Full GRCL calculator →
DIVO
DIVO
● Live price
6.62%
Share price
$44.00
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,008.47
Full DIVO calculator →

Portfolio growth — GRCL vs DIVO

📍 GRCL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRCLDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRCL + DIVO cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GRCL pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRCL
Annual income on $10K today (after 15% tax)
$1,658.54/yr
After 10yr DRIP, annual income (after tax)
$5,435.67/yr
DIVO
Annual income on $10K today (after 15% tax)
$562.67/yr
After 10yr DRIP, annual income (after tax)
$857.20/yr
At 15% tax rate, GRCL beats the other by $4,578.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRCL + DIVO for your $10,000?

GRCL: 50%DIVO: 50%
100% DIVO50/50100% GRCL
Portfolio after 10yr
$50.9K
Annual income
$3,701.69/yr
Blended yield
7.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GRCL right now

GRCL
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Price Target
$6.00
-41.5% upside vs current
Range: $6.00 — $6.00
Altman Z
1.5
Piotroski
3/9
DIVO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRCL buys
0
DIVO buys
0
No recent congressional trades found for GRCL or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRCLDIVO
Forward yield19.51% ✓6.62%
Annual dividend / share$2.00$2.91 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$70.9K ✓$31.0K
Annual income after 10y$6,394.90 ✓$1,008.47
Total dividends collected$39.8K ✓$8.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GRCL vs DIVO ($10,000, DRIP)

YearGRCL PortfolioGRCL Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$12,651$1,951.22$11,362$661.96+$1.3K → GRCL
2$15,844$2,307.04$12,860$702.91+$3.0K → GRCL
3$19,653$2,700.22$14,504$743.56+$5.1K → GRCL
4$24,159$3,130.30$16,303$783.73+$7.9K → GRCL
5$29,447$3,596.27$18,268$823.31+$11.2K → GRCL
6$35,604$4,096.58$20,408$862.17+$15.2K → GRCL
7$42,726$4,629.21$22,737$900.20+$20.0K → GRCL
8$50,908$5,191.72$25,266$937.31+$25.6K → GRCL
9$60,253$5,781.31$28,008$973.42+$32.2K → GRCL
10$70,866$6,394.90$30,977$1,008.47+$39.9K → GRCL

GRCL vs DIVO: Complete Analysis 2026

GRCL — Stock

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Full GRCL Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this GRCL vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRCL vs SCHDGRCL vs JEPIGRCL vs OGRCL vs KOGRCL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.